Waiting for the changes after the adoption of steatotic liver disease
- Author:
Eileen L. YOON
1
;
Dae Won JUN
Author Information
- Publication Type:Special Review
- From:Clinical and Molecular Hepatology 2023;29(4):844-850
- CountryRepublic of Korea
- Language:English
- Abstract: Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease (NAFLD). This was to improve the understanding of the patients and primary care physicians, with an explanation of the pathophysiology in the name of the disease. Also, it could minimize the stigmatization of patients by using the histological neutral term “steatosis” instead of “fatty”. Herein, we will discuss the changes and continuity between the two nomenclatures, metabolic dysfunction-associated steatotic liver disease (MASLD) and NAFLD, as well as the challenges to MASLD which need to be addressed in future.
